Inhibrx Biosciences (INBX) Receivables (2023 - 2025)
Inhibrx Biosciences (INBX) has disclosed Receivables for 3 consecutive years, with $727000.0 as the latest value for Q3 2025.
- On a quarterly basis, Receivables rose 21.17% to $727000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $727000.0, a 21.17% increase, with the full-year FY2024 number at $64000.0, down 91.77% from a year prior.
- Receivables was $727000.0 for Q3 2025 at Inhibrx Biosciences, roughly flat from $730000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $1.1 million in Q2 2024 to a low of $64000.0 in Q4 2024.
- A 3-year average of $640666.7 and a median of $667000.0 in 2023 define the central range for Receivables.
- Peak YoY movement for Receivables: tumbled 89.46% in 2024, then increased 21.17% in 2025.
- Inhibrx Biosciences' Receivables stood at $607000.0 in 2023, then crashed by 89.46% to $64000.0 in 2024, then surged by 1035.94% to $727000.0 in 2025.
- Per Business Quant, the three most recent readings for INBX's Receivables are $727000.0 (Q3 2025), $730000.0 (Q2 2025), and $64000.0 (Q4 2024).